Issues of Type 2 Diabetes Disease Effective Treatment in Kazakhstan


Type 2 diabetes mellitus
cardiovascular system
coronary artery disease
insulin resistance

How to Cite

N.T. Ablaikhanova, A.Y. Yessenbekova, Tazhiyeva Aigul, Z.B. Yessimsiitova, A.K. Saidakhmetova, A.E. Malibayeva, B.J. Sanbaeva, & M. Molsadykkyzy. (2020). Issues of Type 2 Diabetes Disease Effective Treatment in Kazakhstan. Journal of Pharmacy and Nutrition Sciences, 10(3), 116–122.


In his address to the people, the First President of our country, emphasized the need to introduce innovative methods of treating socially significant diseases. Among these diseases, diabetes holds a special position.
More than 14,000 new cases of diabetes mellitus are officially detected annually in Kazakhstan.
The real picture of the disease is difficult to compare with these data. This review discusses the prevalence of type 2 diabetes among the population of the Republic of Kazakhstan, and the causing factors such as age, race, genetic predisposition (OR = 3), obesity, glucose level and total cholesterol etc.
It was found that the main complications and concomitant diseases of diabetes in residents of different regions are polyneuropathy - 22.4%, diabetic retinopathy - 14%, diabetic foot syndrome - 13.6%, arterial hypertension - 13.6% and coronary heart disease (CHD) - 14.4%. Only 1.8% of the population is diagnosed with type 2 diabetes, latent manifestations of type 2 diabetes mellitus, one in four people in Kazakhstan can be sick, 38% of adults aged 20-79 suffer from prediabetes, and 8.2% with diabetes. It is believed that by 2030 in Kazakhstan, there may be about a million patients with diabetes.
Diabetes mellitus, in accordance with the Code of the Republic of Kazakhstan “On the health of the people and the health care system” belongs to the category of socially significant diseases.
Therefore, the study of type 2 diabetes is one of the urgent problems of the public health in Kazakhstan.


Toktarova NN, Bazarbekova RB, Dosanova AK. The prevalence of type 2 diabetes mellitus among the adult population of Kazakhstan (results of the NOMAD registry national study). Medicine (Almaty) 2017; 6(180): 43-51.

Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PAC, Rubin HR. Why don’t physicians follow clinical practices guidelines? A framework of improvement. JAMA 1999; 282(15): 1458-1465.

Geographic patters of childhood insulin-dependent ant diabetes mellitus. Diabetes Epidemiology Research International Group. Diabetes 1998; 37(8): 1113-1119.

Atlas IDF - 7th edition, 2015. Available from:

Consensus on the diagnosis and treatment of diabetes mellitus, MHSD RK, ROO AVEC, edition 4. - Almaty 2016; p. 64.

Kondratov K, Kurapeev D, Popov M, et al. Heparinase treatment of heparin-contaminated plasma from coronary artery bypass grafting patients enables reliable quantification of microRNAs. Biomol Detect Quantif 2016; 8: 9-14.

World Health Organization - Diabetes country profiles, 2016. [Electronic resource

Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R. Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metabolism research and reviews 2001; 17: 363-373.

Tolegenkyzy A, Kachieva ZS, Salimbekova SK, Bismildin GS, Akhmetova JN. Molecular mechanisms of the development of insulin resistance and type 2 diabetes mellitus. Journal Vestnik KazNMU 2018; Almaty.

Atlas of IDF Diabetes Seventh Edition 2015 p. 17. [Electronic resource

Dedov II, Omelyanovsky VV, Shestakova MV, Avksentieva MV, Ignatieva V.I. Diabetes mellitus as an economic problem in the Russian Federation. Diabetes mellitus 2016; 19(1): 30-43.

Opening of the Kazakhstan Society for the Study of Diabetes [Electronic resource

Medinform LLP. Incidence of all cases (prevalence) of diabetes mellitus in the population

Order No. 145 of March 16, 2011 amending the order of the acting Of the Minister of Health of the Republic of Kazakhstan dated November 10, 2009 No. 685 “On approval of the Rules for conducting preventive medical examinations of target population groups”.

Order of the Minister of Health of the Republic of Kazakhstan dated April 5, 2013 No. 211 “On the Implementation of the Program for the Management of Chronic Noncommunicable Diseases in the Pilot Regions”.

Order of the Minister of Health and Social Development of the Republic of Kazakhstan No. 203 dated March 15, 2016 “On some issues of managing chronic non-communicable diseases in the framework of the pilot project”.

Harney F. Diabetic retinopathy. Medicine 2006; 3: 95-98.

Roglic G, Unwin N, Bennett PH. et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2004; 28: 2130-2135.

Rao Kondapally Seshasai S, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. The New England Journal of Medicine 2011; 9: 829-841.

Nwaneri C, Cooper H, Bowen-Jones D. Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. The British Journal of Diabetes and Vascular Disease 2013; 13: 192-207.

Regidor E, Franch J, Seguí M. et al. Traditional risk factors alone could not explain the excess mortality in patients with diabetes: a national cohort study of older Spanish adults. Diabetes Care 2012; 35: 2503-2509.

Luijks H, Schermer T, Bor H, et al. Prevalence and incidence density rates of chronic comorbidity in type 2 diabetes patients: an exploratory cohort study. BMC Medicine 2012; 10: 128.

Teljeur C, Smith SM, Paul G, Kelly A, O’Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. The European Journal of General Practice 2013; 19: 17-22.

Shamshirgaran SM, Mamaghanian A, Aliasgarzadeh A, et al. Age differences in diabetes-related complications and glycemic control. BMC Endocrine Disorders 2017; 1: 25.

Clarke P, Leal, J, Kelman C, Smith M, Colagiuri S. Estimating the cost of complications of diabetes in Australia using administrative health-care data. Value in Health 2008; 2: 199-206.

Pelletier EM, Smith PJ, Boye KS, et al. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: A resource for economic research. Applied Health Economics and Health Policy 2008; 2-3: 103-112.

Berkinbaev SF, Dzhunusbekov GA, Danyarova LB, et al. Epidemiological aspects and prevalence of risk factors for type 2 diabetes among residents of Almaty and the Almaty region of the Republic of Kazakhstan. International Endocrinological Journal 2016; 6: 28-34.

Sliwinska-Mosson M, Milnerowicz H. The impact of smoking on the development of diabetes and its complications. Diabetes and Vascular Disease Research 2017; 4: 265-276.

Levit Sh, Filippov YuI, Gorelyshev AV. Type 2 diabetes: time to change the concept. Diabetes 2013; 1: 91-102.

Hemmingsen B, Lund SS, Gluud C, et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2011; Vol. 6.

Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. Lancet 2009; 373: 1765-1772.

Algorithms for specialized medical care for patients with diabetes mellitus. Edited by II. Dedova, M.V. Shestakova, A.Yu. Mayorova. - 8th edition. - M.: UP PRINT; 2017; p. 112.

OECD (2018), Health Systems Reviews: Kazakhstan 2018, OECD Publishing, Paris. 9789264292895-ru

Suntsov YuI, Kudryakova SV, Bolotskaya LL. The value of the state register of patients with diabetes mellitus in the development of the diabetes service. Diabetes mellitus 2002; 1: 28-31.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright (c) 2020 N.T. Ablaikhanova , A.Y. Yessenbekova , Tazhiyeva Aigul , Z.B. Yessimsiitova , A.K. Saidakhmetova , A.E. Malibayeva , B.J. Sanbaeva, M. Molsadykkyzy